ABSTRACT
Objective: To investigate whether serum level of carbohydrate antigen-125 (CA-125) could predict the new-onset of atrial fibrillation (AF) in patients with chronic heart failure (CHF). Methods: A total of 200 CHF patients without previous and current AF admitted in our hospital from 2012-01 to 2016-01 were enrolled. Serum level of CA-125 was examined in all patients at their stable condition. Follow-up study was conducted to observe AF occurrence in order to evaluate the relationship between CA-125 level and new-onset of AF. Results: There were 8 patients died within 6 months, 14 lost contact and 178 finished at least 1 time follow-up at the mean of (20.1±9.9) months (from 6 to 54 months). 40/178 (22％) patients developed new-onset of AF. Compared with sinus rhythm, AF patients had the higher CA-125 level as 108 (44-228) U/ml vs 49 (21-118) U/ml, P=0.001. ROC indicated that CA-125>72.58 U/ml was the optimal cut-off value for predicting new-onset of AF. Single factor analysis indicated that serum CA-125>72.58 U/ml, increased left atrial diameter, right ventricular dilatation, pulmonary hypertension, lower LVEF and moderate to severe mitral regurgitation (MR) had the predictive value for new-onset of AF. With adjusted meaningful single factors, multivariate Cox regression analysis presented that serum CA-125>72.58 U/ml (HR=2.709, 95％ CI 1.308-6.876, P=0.008) and moderate to severe MR were the independent predictors for new-onset of AF. Conclusion: Serum CA-125 level was related to new-onset of AF in CHF patients; the patients with elevated CA-125 had the higher chance to develop new-onset of AF.
ABSTRACT
Objective: To investigate whether serum level of carbohydrate antigen-125 (CA-125) could predict the new-onset of atrial fibrillation (AF) in patients with chronic heart failure (CHF). Methods: A total of 200 CHF patients without previous and current AF admitted in our hospital from 2012-01 to 2016-01 were enrolled. Serum level of CA-125 was examined in all patients at their stable condition. Follow-up study was conducted to observe AF occurrence in order to evaluate the relationship between CA-125 level and new-onset of AF. Results: There were 8 patients died within 6 months, 14 lost contact and 178 finished at least 1 time follow-up at the mean of (20.1±9.9) months (from 6 to 54 months). 40/178 (22％) patients developed new-onset of AF. Compared with sinus rhythm, AF patients had the higher CA-125 level as 108 (44-228) U/ml vs 49 (21-118) U/ml, P=0.001. ROC indicated that CA-125>72.58 U/ml was the optimal cut-off value for predicting new-onset of AF. Single factor analysis indicated that serum CA-125>72.58 U/ml, increased left atrial diameter, right ventricular dilatation, pulmonary hypertension, lower LVEF and moderate to severe mitral regurgitation (MR) had the predictive value for new-onset of AF. With adjusted meaningful single factors, multivariate Cox regression analysis presented that serum CA-125>72.58 U/ml (HR=2.709, 95％ CI 1.308-6.876, P=0.008) and moderate to severe MR were the independent predictors for new-onset of AF. Conclusion: Serum CA-125 level was related to new-onset of AF in CHF patients; the patients with elevated CA-125 had the higher chance to develop new-onset of AF.